Continuing Education Activity

Docetaxel, in combination with cisplatin, is approved by the Federal Drug Agency (FDA) as a first-line treatment for prostate cancer and is the standard of care for castration-resistant prostate cancer. The medication is effective in non–small cell lung cancer (NSCLC), particularly for patients with poor prognosis or metastatic disease, and is a standard adjunct in breast cancer treatment. Additionally, docetaxel is part of the TEX regimen for advanced gastric cancer and can be considered for stage IV NSCLC after previous therapies. 

This activity focuses on the indications, mechanism of action, and administration of docetaxel. Participating clinicians are equipped to identify adverse drug reactions, clinical monitoring, pharmacokinetics, drug interactions, toxicity, contraindications, and FDA-issued box warnings. An interprofessional team, including oncologists, pharmacists, and nursing staff, is crucial for optimizing cancer treatment outcomes with docetaxel. Effective patient-centered care requires coordination, communication, and collaboration to manage adverse events, monitor progress, and provide comprehensive patient education.

Objectives:

• Evaluate the mechanism of action of docetaxel to consider symptoms and signs of toxicity.
• Identify the indications for docetaxel based on patient history, physical exam, and progression of cancer.
• Assess the adverse effects of docetaxel within a multidrug regimen.
• Implement effective communication among interprofessional team members to improve treatment efficacy for patients who benefit from docetaxel.

Access free multiple choice questions on this topic.

Indications

In combination with cisplatin, docetaxel has been approved by the Federal Drug Agency (FDA) as a first-line agent in the treatment of prostate cancer.[1] Docetaxel is the standard of care in patients with castration-resistant prostate cancer for palliation and prolongation of life.[2] Single-dose docetaxel is generally first-line therapy in patients with non–small cell lung cancers (NSCLC) and poor prognosis. Due to a good tolerability profile, docetaxel is especially effective in preventing progression and extending survival in patients with NSCLC and metastatic disease. Docetaxel is a standard adjunct agent in breast cancer treatment, demonstrating significant improvements in survival in high-risk patients regardless of prognostic factors such as estrogen receptor expression, the degree of nodal involvement, age, menopause status, and schedule of administration.[3] Finally, in conjunction with oxaliplatin and capecitabine, docetaxel completes the triple-agent combination therapy known as the TEX regimen and is indicated for treating advanced gastric cancer.[4] According to the American Society of Clinical Oncology guidelines for stage IV non–small cell lung cancer, for patients who have previously received both checkpoint inhibitor therapy and platinum-based doublet chemotherapy, single-agent docetaxel, with or without ramucirumab can be considered.[5] Combining anlotinib with docetaxel presents a viable therapeutic option for patients with advanced NSCLC who have not responded to initial platinum-based treatments.[6] 

As per the 2023 American Urological Association guidelines (AUA), in de novo metastatic hormone-sensitive prostate cancer, clinicians should offer androgen deprivation therapy in combination with docetaxel and either abiraterone acetate plus prednisone or darolutamide.[7] According to the AUA guidelines, patients with persistent or recurrent high-grade non-muscle invasive bladder cancer within 12 months of completing adequate Bacillus Calmette-Guérin (BCG) therapy (defined as 2 induction courses or 1 induction course plus one maintenance cycle), who are unwilling or unfit for cystectomy after 2 courses of BCG, clinicians may recommend alternative intravesical therapies such as nadofaragene or alternative intravesical chemotherapies like gemcitabine and docetaxel.

FDA-Approved Indications

Breast cancer

• Metastatic disease: Docetaxel exhibits single-agent activity in locally advanced or metastatic breast cancer, which has advanced after prior chemotherapy regimens.
• Adjuvant therapy: When combined with doxorubicin and cyclophosphamide, docetaxel improves outcomes in patients with operable, node-positive breast cancer.

Non-small cell lung cancer

• Platinum-therapy failure: Docetaxel is a viable treatment option for locally advanced or metastatic NSCLC who have failed platinum-based chemotherapy.
• First-line therapy: Docetaxel, in combination with cisplatin, offers a successful treatment strategy for previously untreated patients with unresectable, locally advanced, or metastatic NSCLC.

Castration-resistant prostate cancer: The combination of docetaxel with prednisone provides a therapeutic approach for patients with metastatic castration-resistant prostate cancer (CRPC).

Gastric adenocarcinoma: A cisplatin and fluorouracil-based regimen, potentially including docetaxel, is FDA-approved for advanced gastric adenocarcinoma, including tumors located at the gastroesophageal junction.

Squamous cell carcinoma of the head and neck: Similar to gastric adenocarcinoma, a cisplatin and fluorouracil-based regimen incorporating docetaxel represents an effective induction therapy for patients with locally advanced squamous cell carcinoma of head and neck (SCCHN).

Off-Label Uses

Anaplastic thyroid cancer: According to the American Thyroid Association guidelines for anaplastic thyroid cancer, the use of cytotoxic chemotherapy involving a taxane (docetaxel or paclitaxel), administered with or without anthracyclines (doxorubicin) or platinum-based agents (cisplatin or carboplatin), is recommended for patients undergoing definitive-intention radiation therapy.[8]

Bladder cancer: According to the AUA guidelines, for patients with persistent or recurrent high-grade non-muscle invasive bladder cancer within 12 months of completing adequate Bacillus Calmette-Guérin (BCG) therapy (defined as 2 induction courses or 1 induction course plus one maintenance cycle), who are unwilling or unfit for cystectomy after 2 courses of BCG, clinicians may recommend alternative intravesical therapies such as nadofaragene or alternative intravesical chemotherapies like gemcitabine and docetaxel.[9]

Mechanism of Action

Docetaxel is a second-generation chemotherapeutic agent of the taxane family. A derivative of paclitaxel, the first taxane to hit the market, docetaxel’s primary mechanism of action is to bind β-tubulin, enhancing proliferation and stabilizing conformation.[2] Doing so inhibits the proper assembly of microtubules into the mitotic spindle, arresting the cell cycling during G2/M. Docetaxel also reduces the expression of the BCL2, an anti-apoptotic gene often overexpressed by cancer cells, conferring enhanced survival. By downregulating this gene, tumor cells can more readily undergo apoptosis.[1]

Pharmacokinetics

Absorption: The area under the curve (AUC) is dose-proportional following 70 mg/m² to 115 mg/m² infusions over 1 to 2 hours. Docetaxel’s pharmacokinetics fit a 3-compartment model, with an initial rapid distribution phase followed by a late terminal phase.

Distribution: The steady-state volume of distribution is 113 liters. Docetaxel is approximately 94% protein-bound, mainly to α1-acid glycoprotein, albumin, and lipoproteins. Dexamethasone does not affect docetaxel’s protein binding.

Metabolism: Docetaxel is metabolized primarily by the CYP3A4 isoenzyme.

Excretion: The mean terminal elimination half-life is 116 hours (92 to 135 hours). Approximately 6% of docetaxel is excreted through urine, while about 75% is excreted through feces.

Administration

Available Dosage Forms and Strengths 

Docetaxel is available in parenteral formulations as a 20 mg/2 mL (10 mg/mL) single-dose vial and as 80 mg/8 mL and 160 mg/16 mL (10 mg/mL) multiple-dose vial. When administered intravenously, the dosing schedules have considerable variability. Administration can be a 1-time single dose or at increments varying from weekly to once every 5 weeks.[1][10] The dosing regimen depends on the cancer type and level of treatment aggressiveness.[3][11] Weekly administration is generally mainly restricted to palliating patients with metastatic disease.[12] The mechanism of administration of docetaxel plays a role in minimizing potential toxicity. Administering the drug by loading onto liposomes or micelles enhances the selective uptake by cancer cells expressing specific cellular markers, optimizing intracellular concentration.[13][14]

Adult Dosage

These are general guidelines and institutional protocols to verify dosing, pre-medication, and toxicity-related dose adjustments.

• Breast cancer: 75 mg/m² IV for a single dose on day 1 of a 21-day cycle; give 6 cycles as part of a multi-drug chemotherapy regimen. 

  • For locally advanced or metastatic disease monotherapy: 60 to 100 mg/m² on the first day of a 21-day cycle.
  • For metastatic disease in combination therapy with capecitabine: 75 mg/m² IV for a single dose on day 1 of a 21-day cycle (for anthracycline-resistant disease)
• NSCLC (locally or advanced metastatic disease): 75 mg/m² IV for a single dose on day 1 of a 21-day cycle; use with cisplatin in treatment-naive patients or as monotherapy for platinum-resistant disease.
• Prostatic cancer: 75 mg.m² IV for a single dose on day 1 of a 21-day cycle; give up to 10 cycles with 5 mg prednisone orally twice daily.

  • Off-label dosing for metastatic castration-resistant disease: 75 mg/m² IV for a single dose on day 1 of a 21-day cycle; give 6 cycles.
• Advanced gastric cancer: 75 mg/m² IV for a single dose on day 1 of a 21-day cycle as part of a multi-drug regimen.
• Locally advanced SCHNC: 75 mg/m² IV for a single dose on day 1 of a 21-day cycle; give 3 or 4 cycles as part of a multi-drug chemotherapy regimen.

Specific Patient Populations

Hepatic impairment: Hepatic dose adjustments include avoiding the use of docetaxel when bilirubin is above the upper normal limit. Docetaxel use should also be avoided if aspartate aminotransferase (AST) and alanine aminotransferase (ALT) exceed 1.5 times the upper normal limit and alkaline phosphatase exceeds 2.5 times the upper normal limit.

Renal impairment: Renal dosing adjustment is undefined. Renal insufficiency and renal failure associated with docetaxel treatment are mostly observed in cases where patients are also receiving concomitant nephrotoxic drugs. Use with caution.

Pregnancy considerations: The addition of taxanes to anthracycline-based chemotherapy for breast cancer during pregnancy shows generally favorable obstetric and neonatal outcomes. In a multicenter cohort study of 103 patients, the incidence of grade 3-4 adverse events was low (6.8%), and the live birth rate was high (97.9%). This study supports the safety and efficacy of taxanes during pregnancy when clinically indicated. However, according to product labeling, docetaxel should be used with caution in pregnant women due to the potential to cause fetal harm, as evidenced by animal studies. Before starting docetaxel, confirming the pregnancy status of women who are of reproductive potential is important.

Breastfeeding considerations: Breastfeeding is generally contraindicated during maternal antineoplastic drug therapy. Although no clinical information is available on the use of docetaxel during breastfeeding, discontinuing breastfeeding for 4 to 5 days after a dose is recommended. However, the manufacturer recommends discontinuing breastfeeding 1 week after the last dose. Chemotherapy can adversely affect the normal microbiome and chemical composition of breastmilk, and women who receive chemotherapy during pregnancy are more likely to experience difficulty nursing their infants.

Pediatric patients: The safety and efficacy of docetaxel have not been established in the pediatric population. The medication is used off-label in refractory Ewing sarcoma.

Older patients: Docetaxel dosage selection for older patients should be approached cautiously, considering the higher likelihood of reduced cardiac, hepatic, and renal function, polypharmacy, and concomitant diseases.[15][16][17][18]

Adverse Effects

Common adverse effects seen in patients treated with docetaxel include infusion reactions, myelosuppression, febrile neutropenia, fatigue, diarrhea, and fluid retention. Infusion reactions can range from standard flushing, itching, dyspnea, and fever to potentially life-threatening anaphylactic shock and cardiorespiratory arrest. Myelosuppression is common with the use of cytotoxic drugs. With docetaxel, anemia, neutropenia, leukopenia, and thrombocytopenia are all reported.[3] Systematic review and meta-analysis of docetaxel use in patients with NSCLC showed a significantly increased risk of severe infections, defined as grade 3 or higher, which is a potentially life-threatening adverse effect.[1] Febrile neutropenia is also among the more serious adverse effects associated with significant morbidity and mortality when inappropriately managed.

Patients often experience skin toxicities with docetaxel. Namely, acral erythema, characterized by tingling in the palms and soles followed by edema and tenderness, and erythrodysesthesia, where fixed solitary plaques develop on the skin adjacent to the infusion site, are the most commonly seen. Peripheral neuropathy, both sensory and motor, is arguably the most common long-term adverse effect. This neuropathy, along with fatigue and neutropenia, is often the dose-limiting factor that causes patients to defer further treatment.[10][12] Myalgias and arthralgias are known adverse effects of docetaxel and other drugs in the taxane family; cases reports of myositis are associated with docetaxel, though this is rare.[19]

Docetaxel is known to confer resistance in multiple types of solid tumors. Through the alteration of blood vessels impairing drug distribution, efflux pumps decreasing intracellular drug concentration, alterations in microtubule structure or function evading stabilization by the drug, or the upregulation of anti-apoptotic pathways, tumors eventually adapt to survive the lethal environment created by docetaxel. These adaptations are another treatment-limiting factor with long-term chemotherapy administration.[2]

Drug-Drug Interactions

CYP inhibitors: Amiodarone inhibits CYP3A4, CY2C8, and  P-glycoprotein (P-gp), which are pathways for taxane metabolism. This inhibition can lead to a significant reduction in docetaxel clearance, resulting in the development of severe skin and mucosal toxicity. CYP3A4 metabolizes docetaxel, and the exposure increases 2.2-fold when coadministered with ketoconazole, a potent CYP3A4 inhibitor. Protease inhibitors, especially ritonavir, can also increase docetaxel exposure. The concomitant use of docetaxel with CYP3A4 inhibitors should be avoided due to the risk of increased docetaxel exposure. In patients receiving docetaxel who cannot avoid potent CYP3A4 inhibitors, close monitoring for toxicity is recommended, and a dose reduction should be considered.[20]

SARS-CoV-2 vaccines: COVID-19 vaccination before initiating docetaxel has been associated with an increased risk of severe hypersensitivity reactions. Given the importance of COVID-19 vaccination, especially for patients with cancer, clinicians should be aware of this potential risk to ensure prompt monitoring and treatment of these events. A cohort study found that individuals with a history of taxane reactions were not at higher risk of anaphylaxis to SARS-CoV-2 vaccines. However, a non-IgE-mediated mechanism behind these hypersensitivity reactions cannot be ruled out and may cause mild symptoms. Therefore, caution is still advised.[21]

Contraindications

Absolute contraindications are hypersensitivity reactions and absolute neutrophil count <1500 cells/mm³. Treatment with taxanes is relatively contraindicated in patients with pre-existing lung conditions, such as chronic obstructive pulmonary disorder. A common complication accompanying taxane treatment is pulmonary toxicity. Pulmonary complications can be life-threatening, especially in predisposed patients with compromised lung function, and avoidance is necessary if possible. Additionally, before administering therapy, patients are screened for renal, hepatic, and bone marrow function to establish potential drug tolerability and the adverse drug reactions of treatment.

Box Warnings

• Mortality: Treatment-related mortality with docetaxel is higher in patients with abnormal liver function, those receiving higher doses, and patients with NSCLC previously treated with platinum-based chemotherapy receiving docetaxel at 100 mg/m².
• Hepatotoxicity: Avoid using docetaxel in patients with bilirubin levels above the upper limit of normal (ULN) or in patients with AST and ALT >1.5 × ULN combined with alkaline phosphatase >2.5 × ULN. Patients are at increased risk for severe neutropenia, severe thrombocytopenia, febrile neutropenia, infections, severe stomatitis, and death. Isolated transaminase elevations >1.5 × ULN also correlate with higher rates of febrile neutropenia. Measure bilirubin, AST, ALT, and alkaline phosphatase before each cycle of docetaxel.
• Neutropenia: Do not administer docetaxel to patients with neutrophil counts <1500 cells/mm³. Frequent blood count monitoring is essential as severe neutropenia can lead to infection.
• Hypersensitivity reactions: Avoid docetaxel in patients with severe hypersensitivity to docetaxel or other polysorbate 80-formulated drugs. Severe hypersensitivity reactions can occur despite dexamethasone premedication and require immediate discontinuation of the infusion and appropriate treatment.
• Fluid retention: Severe fluid retention can present as pleural effusion requiring urgent drainage, cardiac tamponade, or ascites.[12][22][23][24]

Warning and Precautions

• Second primary malignancies: Monitoring for delayed acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), non-Hodgkin lymphoma, and renal cancer is recommended.
• Cutaneous reactions: Severe cutaneous adverse reactions have been reported, necessitating dose adjustment or permanent treatment discontinuation.
• Neurologic reactions: Neurologic reactions such as paresthesia and severe peripheral motor neuropathy may occur. If persistent, severe neurosensory symptoms may warrant dose adjustment or discontinuation.
• Embryo-fetal toxicity: Docetaxel can cause fetal harm. The potential risk to a fetus should be communicated, and effective contraception should be used.
• Alcohol content: The alcohol content in docetaxel may affect the central nervous system, potentially impairing the ability to operate machinery or drive immediately following infusion. Tumor lysis syndrome: Tumor lysis syndrome has been associated with the use of docetaxel. Adequate hydration and close monitoring during treatment are recommended for individuals at risk.
• Macular edema: Cystoid macular edema may require treatment discontinuation.[25][26][27]

Monitoring

Following docetaxel infusion, patients undergo monitoring for infusion reactions, skin toxicities, fever, other signs of infection, and pneumonitis. Additionally, severe diarrhea or new-onset abdominal pain should warrant further evaluation and surgical consultation, as these patients are at an increased risk for bowel perforation. Patients are also advised to monitor for increased fluid accumulations, such as swelling in the fingers, ankles, and mid-abdominal areas. Increased permeability of the capillaries purportedly causes fluid retention. Swelling is an indication for the administration of dexamethasone or diuretics to limit progression to more severe conditions of fluid retention, such as pleural or pericardial effusion.[12]

Toxicity

Signs and Symptoms of Overdose

Dose-dependent pulmonary toxicity has correlations with the administration of docetaxel. Acute bilateral interstitial pneumonitis has been demonstrated to occur during, immediately, and after the initial administration of the drug. Symptoms include dyspnea on exertion, a dry cough, fever, and malaise. The mechanism of action underlying this pulmonary toxicity is poorly understood, but the belief is that an immune-mediated reaction occurs. In treating this toxicity, supportive care is usually sufficient to return patients to their baseline lung function. However, in patients showing clinical signs of either oxygen desaturation or possible respiratory failure, an empiric trial of glucocorticoids has proven effective in relieving pneumonitis.[12]

Management of Overdose

No known antidote exists for docetaxel overdose. Anticipated complications comprise bone marrow suppression, peripheral neurotoxicity, and mucositis. Granulocyte colony-stimulating factor (G-CSF) administration and symptomatic treatment are recommended. G-CSF significantly reduces the risk of febrile neutropenia.[28]

Enhancing Healthcare Team Outcomes

A broad range of clinical expertise plays a role in cancer treatment. Medical oncologists, radiation oncologists, specialists of involved systems (ie, urologists in prostate cancer), and supporting staff all play a role in optimizing treatments and outcomes based on patients’ needs and wishes. Proper monitoring, managing adverse events and acquired comorbidities, counseling, and education on the treatment options can be considered interprofessional responsibilities.

An oncology-specialized pharmacist should be part of the treatment team to verify dosing and potential drug interactions, along with oncology-trained nursing staff trained in administering chemotherapy agents and possible adverse effects. Delivering patient-centered care requires coordination and correspondence between multiple care disciplines. An interprofessional team approach and open communication between clinicians (MD, DO, NP, PA), pharmacists, specialists, nurses, and specialists are necessary to optimize patient outcomes with docetaxel therapy.[29]

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Du Q, Jiang G, Li S, Liu Y, Huang Z. Docetaxel increases the risk of severe infections in the treatment of non-small cell lung cancer: a meta-analysis. Oncoscience. 2018 Jul;5(7-8):220-238. [PMC free article: PMC6142895] [PubMed: 30234144]

2.

Antonarakis ES, Armstrong AJ. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2011 Sep;14(3):192-205. [PMC free article: PMC3444817] [PubMed: 21577234]

3.

Kim SB, Sayeed A, Villalon AH, Shen ZZ, Shah MA, Hou MF, Nguyen Ba D. Docetaxel-based adjuvant therapy for breast cancer patients in Asia-Pacific region: Results from 5 years follow-up on Asia-Pacific Breast Initiative-I. Asia Pac J Clin Oncol. 2016 Jun;12(2):125-32. [PubMed: 26891467]

4.

Ostwal V, Bose S, Sirohi B, Poladia B, Sahu A, Bhargava P, Doshi V, Dusane R, Nashikkar C, Shrikhande SV, Ramaswamy A. Docetaxel/Oxaliplatin/Capecitabine (TEX) triplet followed by continuation monotherapy in advanced gastric cancer. Indian J Cancer. 2018 Jan-Mar;55(1):88-93. [PubMed: 30147101]

5.

Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, Masters G, Schenk EL, Schneider BJ, Sequist L, Singh N, Bazhenova L, Blanchard E, Freeman-Daily J, Furuya N, Halmos B, Azar IH, Kuruvilla S, Mullane M, Naidoo J, Reuss JE, Spigel DR, Owen DH, Patel JD. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3. J Clin Oncol. 2024 Apr 10;42(11):e23-e43. [PubMed: 38417098]

6.

Pu X, Xiao Z, Li J, Wu Z, Ma Z, Weng J, Xiao M, Chen Y, Cao Y, Cao P, Wang Q, Xu Y, Li K, Chen B, Xu F, Liu L, Kong Y, Zhang H, Duan H, Wu L. Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial. Lung Cancer. 2024 May;191:107538. [PubMed: 38552544]

7.

Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, Buckley DI, Griffin JC, Cookson MS. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). J Urol. 2023 Jun;209(6):1082-1090. [PubMed: 37096583]

8.

Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ, Di Cristofano A, Foote R, Giordano T, Kasperbauer J, Newbold K, Nikiforov YE, Randolph G, Rosenthal MS, Sawka AM, Shah M, Shaha A, Smallridge R, Wong-Clark CK. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid. 2021 Mar;31(3):337-386. [PMC free article: PMC8349723] [PubMed: 33728999]

9.

Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC, Kirkby E, McKiernan JM, Schuckman AK. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment. J Urol. 2024 Apr;211(4):533-538. [PubMed: 38265030]

10.

Parikh M, Pan CX, Beckett LA, Li Y, Robles DA, Aujla PK, Lara PN. Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study. Clin Genitourin Cancer. 2018 Dec;16(6):421-428.e1. [PMC free article: PMC6450697] [PubMed: 30166228]

11.

Sakaguchi M, Maebayashi T, Aizawa T, Ishibashi N. Docetaxel-induced radiation recall dermatitis with atypical features: A case report. Medicine (Baltimore). 2018 Sep;97(36):e12209. [PMC free article: PMC6133587] [PubMed: 30200132]

12.

Ho MY, Mackey JR. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res. 2014;6:253-9. [PMC free article: PMC4041377] [PubMed: 24904223]

13.

Kushwah V, Jain DK, Agrawal AK, Jain S. Improved antitumor efficacy and reduced toxicity of docetaxel using anacardic acid functionalized stealth liposomes. Colloids Surf B Biointerfaces. 2018 Dec 01;172:213-223. [PubMed: 30172202]

14.

Varshosaz J, Enteshari S, Hassanzadeh F, Hashemi-Beni B, Minaiyan M, Sadeghian-Rizi S. Synthesis and In vitro/In vivo Characterization of Raloxifene Grafted Poly(Styrene Maleic Acid)-Poly(Amide-Ether-Ester-Imide) Micelles for Targeted Delivery of Docetaxel in G Protein-Coupled Estrogen Receptor Breast Cancer. Anticancer Agents Med Chem. 2018;18(14):2017-2031. [PubMed: 30205803]

15.

Ferrigno Guajardo AS, Vaca-Cartagena BF, Mayer EL, Bousrih C, Oluchi O, Saura C, Peccatori F, Muñoz-Montaño W, Cabrera-Garcia A, Lambertini M, Corrales L, Becerril-Gaitan A, Sella T, Newman AB, Pistilli B, Martinez A, Ortiz C, Joval-Ramentol L, Scarfone G, Buonomo B, Lara-Medina F, Sanchez J, Arecco L, Ramos-Esquivel A, Susnjar S, Morgan G, Villarreal-Garza C, Azim HA. Taxanes for the treatment of breast cancer during pregnancy: an international cohort study. J Natl Cancer Inst. 2024 Feb 08;116(2):239-248. [PubMed: 38059798]

16.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Sep 15, 2023. Docetaxel. [PubMed: 29999960]

17.

Yoon JH, Kwon MM, Park HJ, Park SY, Lim KY, Joo J, Park BK. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors. BMC Cancer. 2014 Aug 28;14:622. [PMC free article: PMC4155244] [PubMed: 25164234]

18.

Mora J, Cruz CO, Parareda A, de Torres C. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol. 2009 Oct;31(10):723-9. [PubMed: 19727011]

19.

Thomas J, Warrier A, Kachare N. Docetaxel-Induced Myositis. J Clin Rheumatol. 2020 Apr;26(3):e62-e63. [PubMed: 30148754]

20.

Hammann F, Gotta V, Conen K, Medinger M, Cesana P, Rochlitz C, Taegtmeyer AB. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. Br J Clin Pharmacol. 2017 Apr;83(4):927-930. [PMC free article: PMC5346859] [PubMed: 27868228]

21.

Cortellini G, Raiteri A, Biagioni B, Liberati S, Lippolis D, Cortellini G, Piscaglia F. Taxanes hypersensitivity is not a risk factor for severe reactions to SARS-CoV-2 vaccines. Eur Ann Allergy Clin Immunol. 2023 Sep;55(5):229-234. [PubMed: 36047485]

22.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Oct 13, 2020. Docetaxel. [PMC free article: PMC547852] [PubMed: 31644206]

23.

Schwartzberg LS, Navari RM. Safety of Polysorbate 80 in the Oncology Setting. Adv Ther. 2018 Jun;35(6):754-767. [PMC free article: PMC6015121] [PubMed: 29796927]

24.

Tsuji K, Kito Y, Miyajima S, Yonezawa M, Kubo A, Ushijima K, Doyama H. Docetaxel-induced fluid retention during adjuvant chemotherapy with S-1 plus docetaxel. Clin J Gastroenterol. 2021 Feb;14(1):84-87. [PubMed: 33070263]

25.

Cheng HL, Molassiotis A, Leung AKT, Wong KH. Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients Treated with Adjuvant or Neo-Adjuvant Chemotherapy. Breast Care (Basel). 2021 Jun;16(3):269-275. [PMC free article: PMC8248780] [PubMed: 34248468]

26.

Cheng S, Awad NI, Toomey KC, Gibson Z, Chari V, Brunetti L. Can ethanol intoxication secondary to docetaxel be predicted based on dose administered using a point-of-care saliva ethanol test? J Oncol Pharm Pract. 2019 Mar;25(2):289-294. [PubMed: 28942719]

27.

Torrado LA, Fivgas GD. Unilateral cystoid macular edema and bilateral subfoveal hyperreflectivity following docetaxel chemotherapy: A case report. Am J Ophthalmol Case Rep. 2020 Dec;20:100995. [PMC free article: PMC7749406] [PubMed: 33367153]

28.

Zekri J, Nawaz A, Rasool H, Ahmad I, Abdel Rahman H, Dada R, Abdelghany EM, Farag K, Ibrahim RB, Deibas MY, Kamel MK, Allithy A. Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer. J Oncol Pharm Pract. 2022 Dec;28(8):1681-1686. [PubMed: 34342555]

29.

Bahl A, Bellmunt J, Oudard S. Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies. BJU Int. 2012 Mar;109 Suppl 2:14-9. [PubMed: 22257100]

Disclosure: Nicole Farha declares no relevant financial relationships with ineligible companies.

Disclosure: Anup Kasi declares no relevant financial relationships with ineligible companies.